Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MIF | P14174 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.41 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.41 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25271685 | 0.85 | PLAU (0.45) | MEN1KMT2ALMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL645203 | 0.84 | LMNA (0.59) | KMT2ALMNAALDH1A1SMN1; SMN2CA2 | |
| SCHEMBL11722992 | 0.80 | MEN1 (0.55) | MEN1KMT2AMIFLMNAIDO1 | |
| SCHEMBL452919 | 0.80 | MEN1 (0.55) | MEN1KMT2AMIFLMNAIDO1 | |
| SCHEMBL6395921 | 0.79 | IDO1 (0.53) | IDO1ALDH1A1 | |
| SCHEMBL8314405 | 0.77 | MEN1 (0.61) | MEN1KMT2ALMNAIDO1ALDH1A1 | |
| SCHEMBL10438809 | 0.77 | MEN1 (0.61) | MEN1KMT2AMIFLMNAIDO1 | |
| SCHEMBL13590480 | 0.76 | TOP2A (0.54) | MEN1KMT2AMIFESR1ESR2 | |
| SCHEMBL20497346 | 0.76 | MEN1 (0.50) | MEN1KMT2AMIF | |
| SCHEMBL27571682 | 0.76 | TSHR (0.51) | MEN1KMT2AMIFLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238711-B1 | Compounds and methods to inhibit or augment an inflammatory response | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2007-07-03 | — | — | US | claimed |
| US-8481558-B2 | Compounds to inhibit or augment an inflammatory response | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| EP-2386565-A2 | Compounds and methods to inhibit or augment an inflammatory response | Cambridge Enterprise Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-7989466-B2 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. | 2008-02-21 | — | — | US | disclosed |
| US-7238711-B1 | Compounds and methods to inhibit or augment an inflammatory response | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2007-07-03 | — | — | US | disclosed |
| EP-1141011-A2 | COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | NEORX CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000042071-A2 | COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045557-A1 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CCL2, CCL11, CCL5 | MEN1 2434/4885KMT2A 4857/4885MIF 27/4885 |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CCL2, CCL5, CCL11 | MEN1 4511/4885KMT2A 4863/4885MIF 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.